Terminated PHASE2 INTERVENTIONAL 4-arm NCT00578097

Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder

A Phase II, International, Multi-centre, Prospective, Randomised, Parallel-group, Double-blind, Dose-ranging, Placebo-controlled, 12-week, Princeps Study to Assess the Efficacy and Safety of a One Injection Cycle With Either Botulinum Toxin Type-A (Dysport® 125, 250 or 500 Units) or Placebo Followed by an Optional 6-month Extension Phase in the Symptomatic Treatment of Micturition Urgency and Frequency in Continent Female Subjects Suffering From Idiopathic Overactive Bladder.

Sponsor: Ipsen

Conditions Overactive Bladder

Interventions Botulinum toxin type A Placebo

Updated 10 times since 2017 Last updated: Nov 21, 2019 Started: Feb 29, 2008 Primary completion: Jun 30, 2009 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was terminated early due to poor recruitment.

Other terminated trials from Ipsen

See all terminations from Ipsen

Other Overactive Bladder trials with similar outcome

Browse all Overactive Bladder trials

This PHASE2 trial investigates Overactive Bladder and is currently terminated or withdrawn. Ipsen leads this study, which shows 10 recorded versions since 2008 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2019 — Jan 2021 [monthly]

Terminated PHASE2

▶ Show 5 earlier versions

Sep 2019 — Dec 2019 [monthly]

Terminated PHASE2
Aug 2019 — Sep 2019 [monthly]

Terminated PHASE2
Feb 2019 — Aug 2019 [monthly]

Terminated PHASE2
Jun 2018 — Feb 2019 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ipsen

Data source: Ipsen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Amsterdam, Netherlands , Bad Kreuznach, Germany , Bristol, United Kingdom , Brussels, Belgium , Edinburgh, United Kingdom , Emmendingen, Germany , Florence, Italy , Grenoble, France , Günzburg, Germany and 24 more locations